Novel imidazole-based histamine H3 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 3, 2009, Pages 903-907

  Jablonowski, Jill A ^a   Ly, Kiev S ^a   Bogenstaetter, Michael ^a   Dvorak, Curt A ^a   Boggs, Jamin D ^a   Dvorak, Lisa K ^a   Lord, Brian ^a   Miller, Kirsten L ^a   Mazur, Curt ^a   Wilson, Sandy J ^a   Lovenberg, Timothy W ^a   Carruthers, Nicholas I ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Benzoylimidazole; Blood brain barrier penetration; Histamine H3; Imidazole; Metabolic stability

Indexed keywords

(4 CHLOROPHENYL)[2 (1 ISOPROPYLPIPERIDIN 4 YLMETHOXY) 3 METHYL 3H IMIDAZOL 4 YL]METHANONE; CIPROXIFAN; CLOBENPROPIT; CYTOCHROME P450; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; JB 98064; THIOPERAMIDE; UCL 1972; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; LIVER MICROSOME; NONHUMAN; RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; HISTAMINE H3 ANTAGONISTS; HUMANS; IMIDAZOLES; LIGANDS; MODELS, CHEMICAL; PROTEIN BINDING; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58549094690     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.114     Document Type: Article

References (23)

1. Barger G., and Dale H.H. J. Physiol. 41 (1910) 19
2. Black J.W., Duncan W.A.M., Durant G.J., Ganellin C.R., and Parsons M.E. Nature 236 (1972) 385
3. Arrang J.-M., Garbarg M., and Schwartz J.-C. Nature 302 (1983) 832
4. Liu C., Ma X.-J., Jiang X., Wilson S.J., Hofstra C., Blevitt J., Pyati J., Li X., Chai W., Carruthers N., and Lovenberg T.W. Mol. Pharmacol. 59 (2001) 420
5. Lovenberg T.W., Roland B.L., Wilson S.J., Jiang X., Pyati J., Huvar A., Jackson M.J., and Erlander M.G. Mol. Pharmacol. 55 (1999) 1101
6. Celanire S., Wijtmans M., Talaga P., Leurs R., and de Esch I.J.P. Drug Disc. Today 10 (2005) 1613
7. Murray M. Drug Metab. Rev. 18 (1987) 55
8. Yang R., Hey J.A., Aslanian R., and Rizzo C.A. Pharmacology 66 (2002) 128
9. Ganellin C.R., Leurquin F., Piripitsi A., Arrang J.-M., Garbarg M., Ligneau X., Schunack W., and Schwartz J.-C. Arch. Pharm. (Weinheim) 331 (1998) 395
10. Linney I.D., Buck I.M., Harper E.A., Kalindjian S.B., Pether M.J., Shankley N.P., Watt G.F., and Wright P.T. J. Med. Chem. 43 (2000) 2362
11. Shah C., McAtee L., Breitenbucher J.G., Rudolph D., Li X., Lovenberg T.W., Mazur C., Wilson S.J., and Carruthers N.I. Bioorg. Med. Chem. Lett. 12 (2002) 3309
12. Bonaventure P., Letavic M., Dugovic C., Wilson S., Aluisio L., Pudiak C., Lord B., Mazur C., Kamme F., Nishino S., Carruthers N., and Lovenberg T. Biochem. Pharmacol. 73 (2007) 1084
13. Stocking E.M., and Letavic M.A. Curr. Top. Med. Chem. 8 (2008) 988
14. Kovalainen J.T., Christiaans J.A.M., Ropponen R., Poso A., Peraekylae M., Vepsaelaeinen J., Laatikainen R., and Gynther J. J. Am. Chem. Soc. 122 (2000) 6989
15. Barbier A.J., Berridge C., Dugovic C., Leposky A.D., Wilson S.J., Boggs J., Aluisio L., Lord B., Mazur C., Pudiak C.M., Langlois X., Xiao W., Apodaca R., Carruthers N.I., and Lovenberg T.W. Br. J. Pharmacol. 143 (2004) 649
16. Dvorak C.A., Apodaca R., Barbier A.J., Berridge C.W., Wilson S.J., Boggs J.D., Xiao W., Lovenberg T.W., and Carruthers N.I. J. Med. Chem. 48 (2005) 2229
17. Compound 25 exhibited a disconnect between receptor binding affinity and functional activity for which we have no explanation.
18. Bogenstaetter M., Carruthers N.I., Jablonowski J.A., Lovenberg T.W., and Ly K.S. Chem. Abstr. 137 (2002) 279192 WO 2002079168, 2002
19. Ohta S., Yamamoto T., Kawasaki I., Yamashita M., Katsuma H., Nasako R., Kobayashi K., and Ogawa K. Chem. Pharm. Bull. 40 (1992) 2681
20. Phillips B.T., Claremon D.A., and Varga S.L. Synthesis (1990) 761
21. Jarosinski M.A., and Anderson W.K. J. Org. Chem. 56 (1991) 4058
22. Shapiro G., and Marzi M. Tetrahedron Lett. 34 (1993) 3401
23. Mani N.S., Jablonowski J.A., and Jones T.K. J. Org Chem. 69 (2004) 8115